checkedThe Carlat Psychiatry Podcast2026-11-09last verified 2026-11-09

did a review find six wernicke encephalopathy cases on semaglutide, mostly women in their 40s?

verdict: overstated
directionally right; magnitude or certainty inflated
“The authors found six case reports of warnakies on semi-glutide. Most were women in their 40s who had taken semi-glutide for about five months before symptoms began.”

a host, a psychiatrist said on The Carlat Psychiatry Podcast, 2026-11-09, at 13:38. hear it in context → the speaker cited: a systematic review of case reports on semaglutide in the journal Obesity.

the episode: Kraepelin on Clancy Part 2 (at 13:38). we link the show's own page; we do not re-host audio.

first, the part that holds

the review is real and the speaker's numbers match it: a systematic review in the journal Obesity found six cases of wernicke encephalopathy after semaglutide prescribed for weight loss, four of the six were women, the mean age was 47.2, and the mean time on semaglutide was 4.9 months.

what we found when we went and looked

we read the full text of the review (Obesity, 2026, open access on PMC). it identified "six unique cases" of wernicke encephalopathy in people prescribed semaglutide for weight loss: four women and two men, mean age 47.2 (SD 13.9, range 37–74), mean time on semaglutide 4.9 months (range 2.5–12). the count, the female majority and the "about five months" all hold. the one gap is "most were women in their 40s": the paper gives a group mean of 47 with an age range running to 74, and in what we could read it does not say that most patients, or most of the women, were in their 40s. that turns an average into a description of the typical patient. it is a narrow gap and does not change what the review found.

assertion by assertion

assertionverdictwhat the record says
a systematic review of case reports in the journal Obesity looked at wernicke encephalopathy on semaglutideconfirmed"Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence," Obesity vol. 34 suppl. 2, 2026, Dutch authors. it searched PubMed, Embase, CINAHL and Scopus, with searches run on February 10, 2026. [1]
the authors found six case reportsconfirmedthe review reports "six unique cases diagnosed with WE in patients who were prescribed Ozempic or Wegovy for weight loss." six counts only the published case reports with enough detail to include. it is not a count of every case that has occurred. [1]
most were women in their 40soverstatedfour of six were women, so the female majority holds. age is reported only as a group figure: mean 47.2, SD 13.9, range 37–74. in the full text we read, the review does not say how many patients, or how many of the women, were in their 40s. a mean of 47 with one patient at 74 is consistent with several different age mixes, so "most were in their 40s" claims more than the paper shows. [1]
about five months of semaglutide use before symptoms beganconfirmed"patients had an average duration of semaglutide treatment of 4.9 months (SD: 3.6 months, range: 2.5–12 months)." this is a mean, and individual cases ranged from about ten weeks to a year. [1]
popular framing: six case reports show how often semaglutide causes wernicke encephalopathyunverifiablecase reports have no denominator, so they cannot give a rate. the review itself says "comorbidities and concomitant medications could have contributed to nutritional deficiency, complicating causal attribution", and five of the six patients had several comorbidities. at least one other published case of severe thiamine deficiency on semaglutide was diagnosed as a different syndrome (acute nutritional axonal neuropathy), so a review limited to wernicke encephalopathy will not capture every thiamine-related neurological harm. [1][2]

both directions

for the speaker: the journal, the study design, the six cases, the four-of-six female split and the roughly five months of use all match the full text. the review also supports the seriousness implied on the show. before the neurological symptoms, every patient had prolonged gastrointestinal symptoms and substantial weight loss: loss of appetite in five of six, weakness in four, vomiting in three. outcomes were poor. one patient died, four developed lasting memory problems consistent with korsakoff syndrome, and only one recovered well.

against: "in their 40s" is the speaker's rendering of a mean age of 47.2. the range of 37 to 74 includes at least one patient in their 70s, and the paper as we read it gives no breakdown showing a majority in their 40s. the "about five months" is also a mean that hides wide spread (2.5 to 12 months). none of these figures speaks to how common the condition is, and the authors themselves say comorbidities and other medications make it hard to attribute the cases to semaglutide.

what this cannot say

we read the open-access full text on PMC. the publisher's version and the PubMed abstract page would not load for us, and the text we read had no table of individual cases, so we could not check each patient's age directly. if the publisher's version has a case table, it could settle the 40s question either way. six published case reports reflect what clinicians chose to write up and journals chose to publish. they say nothing about incidence, and they cannot separate the effect of semaglutide from vomiting, poor intake and comorbid illness. our second source is one case report, cited only to show that thiamine-related harms on semaglutide can fall outside a wernicke-only search.

sources, each one fetched and read

  1. Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence. Obesity (Silver Spring), vol. 34, suppl. 2, 2026. doi:10.1002/oby.70256 What we read there: six unique cases were diagnosed with WE in patients prescribed semaglutide for weight loss: four female and two male. "The mean age was 47.2 (SD: 13.9, range: 37–74 years)". "patients had an average duration of semaglutide treatment of 4.9 months (SD: 3.6 months, range: 2.5–12 months)". one patient died, one had a good outcome, and four had chronic korsakoff syndrome. "comorbidities and concomitant medications could have contributed to nutritional deficiency, complicating causal attribution." Fetched 2026-11-09 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC13535703/
  2. Acute Nutritional Axonal Neuropathy in the Setting of Semaglutide-Associated Gastrointestinal Intolerance: A Case Report. Case Reports in Neurology, 2026 What we read there: "A 65-year-old woman with type 2 diabetes and obesity presented with profound weakness, cranial nerve deficits, dysphagia, and a 120-pound weight loss after months of semaglutide therapy with persistent nausea and vomiting." serum thiamine was 25 nmol/L (normal 70–180). the diagnosis was acute nutritional axonal neuropathy, not wernicke encephalopathy. Fetched 2026-11-09 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC13432944/

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam